A "very rigid" structure for a rare disease center of excellence would not necessarily improve application reviews or the program's' visibility within the US FDA, Janet Woodcock, director of the Center for Drug Evaluation and Research, told advocates.
The future of application review across CDER is a more flexible review team structure, where expertise from many different specialties can be accessed as needed. Woodcock said rare diseases need...